Literature DB >> 21303827

Immunoadsorption (IAS) for systemic lupus erythematosus.

G H Stummvoll.   

Abstract

Immunoadsorption (IAS) is used as a rescue therapy in severely ill SLE patients who are refractory to conventional therapies. This extracorporeal method aims at the rapid and extensive removal of pathogenic immunocomplexes (ICs) and (auto-)antibodies (Abs). Although past data have shown short- to mid-term efficacy and biocompatibility of IAS in (renal) SLE, it is still an experimental and rather expensive procedure - and evidence from randomized controlled trials (RCTs) is lacking. Nevertheless, IAS is successfully used in life-threatening situations because of its fast mode of action and its acceptable safety profile.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21303827     DOI: 10.1177/0961203310389487

Source DB:  PubMed          Journal:  Lupus        ISSN: 0961-2033            Impact factor:   2.911


  2 in total

1.  Rapid reduction of antibodies and improvement of disease activity by immunoadsorption in Chinese patients with severe systemic lupus erythematosus.

Authors:  Jinxian Huang; Guoxiang Song; Zhihua Yin; Weizhen He; Lijun Zhang; Weihong Kong; Zhizhong Ye
Journal:  Clin Rheumatol       Date:  2016-08-03       Impact factor: 2.980

2.  Immunoadsorption Improves Remission Rates of Patients with Antineutrophil Cytoplasmic Antibody-Associated Vasculitis and Severe Kidney Involvement.

Authors:  Xiaoxin Chu; Yu Hong; Yuxi Wang; Chong Yu; Lisheng Wang; Hui Tong; Jianjun Yan; Zhonghua Zhang; Gang Xu; Ying Yao; Rui Zeng
Journal:  Am J Nephrol       Date:  2021-12-07       Impact factor: 3.754

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.